Palmitoylethanolamide modulates inflammation-associated Vascular Endothelial Growth Factor (VEGF) signaling via the Akt/mTOR pathway in a selective peroxisome proliferator-activated receptor alpha (PPAR-α)-dependent manner

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Sarnelli, Giovanni ^a   D'Alessandro, Alessandra ^a   Iuvone, Teresa ^a   Capoccia, Elena ^b   Gigli, Stefano ^b   Pesce, Marcella ^a   Seguella, Luisa ^b   Nobile, Nicola ^b   Aprea, Giovanni ^a   Maione, Francesco ^a   De Palma, Giovanni Domenico ^a   Cuomo, Rosario ^a   Steardo, Luca ^b   Esposito, Giuseppe ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE; VASCULOTROPIN; DEXTRAN SULFATE; ETHANOLAMINE DERIVATIVE; MTOR PROTEIN, HUMAN; PALMITIC ACID DERIVATIVE; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; ULCERATIVE COLITIS; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; COLITIS; COLITIS, ULCERATIVE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION;

ADULT; ANIMALS; CELLS, CULTURED; COLITIS; COLITIS, ULCERATIVE; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ETHANOLAMINES; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; PALMITIC ACIDS; PPAR ALPHA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84973866694     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0156198     Document Type: Article

References (58)

1. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res. 2002; 4:81-90.
2. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009; 218:7-29. doi: 10.1002/path.2518 PMID: 19309025
3. Crawford TN, Alfaro DV 3rd, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev. United Arab Emirates; 2009 Feb; 5(1):8-13.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407:249-57. PMID: 11001068
5. Tas SW, Maracle CX, Balogh E, Szekanecz Z. Targeting of proangiogenic signalling pathways in chronic inflammation. Nat Rev Rheumatol. 2016 Feb; 12(2):111-22. doi: 10.1038/nrrheum.2015.164 PMID: 26633288
6. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence inflammation of angiogenesis and chronic. FASEB J. 1997; 11:457-65. PMID: 9194526
7. Alkim C, Alkim H, Koksal AR, Boga S, Sen I. Angiogenesis in Inflammatory Bowel Disease. Int J Inflam. 2015; 2015:970890 doi: 10.1155/2015/970890 PMID: 26839731
8. Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. AGA Institute American Gastroenterological Association; 2006 Jun; 130(7):2060-73.
9. Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006 May; 7(5):359-71. PMID: 16633338
10. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999; 56:794-814. PMID: 10469350
11. Davaatseren M, Hwang J-T, Park JH, Kim M-S, Wang S, Sung MJ. Allyl isothiocyanate ameliorates angiogenesis and inflammation in dextran sulfate sodium-induced acute colitis. PLoS One. 2014 Jan; 9(7):e102975. doi: 10.1371/journal.pone.0102975 PMID: 25051185
12. Son MK, Jung KH, Hong S-W, Lee H-S, Zheng H-M, Choi M-J, et al. SB365, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/mTOR signalling pathway. Food Chem. Elsevier Ltd; 2013 Jan; 136(1):26-33.
13. Karar J, Maity A. PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci. 2011 Jan; 4(51):1-8.
14. Clottes E. Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy. Bull Cancer. 2005 Feb; 92(2):119-27. PMID: 15749641
15. Hadjipanayi E, Schilling AF. Hypoxia-based strategies for angiogenic induction: the dawn of a new era for ischemia therapy and tissue regeneration. Organogenesis. 2013 Oct 1; 9(4):261-72. doi: 10.4161/org.25970 PMID: 23974216
16. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-alpha Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide. Mol Pharmacol. 2005; 67(1):15-9. PMID: 15465922
17. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol. 2002; 135:181-7. PMID: 11786493
18. Costa B, Conti S, Giagnoni G, Colleoni M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol. 2002 Oct; 137(4):413-20. PMID: 12359622
19. Ross R a., Brockie HC, Pertwee RG. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur J Pharmacol 2000 Aug; 401(2):121-30. PMID: 10924916
20. Farquhar-smith WP, Jaggar SI, Rice ASC. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB 1 and CB 2 -like receptors. Pain. 2002; 97:11-21. PMID: 12031775
21. De Filippis D, D'Amico A, Cipriano M, Petrosino S, Orlando P, Di Marzo V, et al. Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacol Res. Elsevier Ltd; 2010 Apr; 61(4):321-8.
22. Cipriano M, Esposito G, Negro L, Capoccia E, Sarnelli G, Scuderi C, et al. Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of beta Amyloid-Induced Astrogliosis In Vitro. CNS Neurol Disord Drug Targets. United Arab Emirates; 2015; 14(7):828-37.
23. Sarnelli G, Gigli S, Capoccia E, Iuvone T, Cirillo C, Seguella L et al. Antiproliferative and antiangiogenic effects of palmitoylethanolamide in Caco-2 human colon cancer cell involve a selective PPAR-alpha dependent inhibition of Akt/mTOR pathway. Phytotherapy Research; 2016 2016 Mar 1. [Epub ahead of print]
24. Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F, Mascolo N, et al. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol. 2001; 134:945-50. PMID: 11682441
25. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. International Association for the Study of Pain; 2008 Oct 3; 139(3):541-50.
26. Brown WH, Gillum MP, Lee H, Paulo J, Camporez G, Zhang X. Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism. Proc Natl Acad Sci USA. 2012; 109:14966-71. doi: 10.1073/pnas.1212887109 PMID: 22912404
27. Esposito G, Capoccia E, Turco F, Palumbo I, Lu J, Steardo A, et al. Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation. Gut. 2014 Aug; 63(8):1300-12. doi: 10.1136/gutjnl-2013-305005 PMID: 24082036
28. Tsujii M, Kawano S, Tsuji S, Kobayashi I, Takei Y, Nagano K, et al. Colonic mucosal hemodynamics and tissue oxygenation in patients with ulcerative colitis: investigation by organ reflectance spectrophotometry. Gastroenterol. 1995 Apr; 30(2):183-8.
29. Bhaskar L, Ramakrishna BS, Balasubramanian KA. Colonic mucosal antioxidant enzymes and lipid peroxide levels in normal subjects and patients with ulcerative colitis. J Gastroenterol Hepatol. 1995 Mar-Apr; 10(2):140-3. PMID: 7787158
30. Grevenitis P, Thomas A, Lodhia N. Medical Therapy for Inflammatory Bowel Disease. Surg Clin North Am. 2015 Dec; 95(6):1159-82. doi: 10.1016/j.suc.2015.08.004 PMID: 26596920
31. Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, et al. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol. 2015 Aug 17; 8:257-69. doi: 10.2147/CEG.S58152 PMID: 26316792
32. Setia S, Nehru B, Sanyal SN. The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor. Biomed Pharmacother. Elsevier Masson SAS; 2014 Jul; 68(6):721-7.
33. Hatoum O a, Heidemann J, Binion DG. The intestinal microvasculature as a therapeutic target in inflammatory bowel disease. Ann N Y Acad Sci 2006 Aug; 1072:78-97. PMID: 17057192
34. Chidlow JH, Langston W, Greer JJM, Ostanin D, Abdelbaqi M, Houghton J, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol [Internet]. American Society for Investigative Pathology; 2006 Dec; 169(6):2014-30.
35. Ferrante M, Pierik M, Henckaerts L, Joossens M, Claes K, Van Schuerbeek N, et al. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis. 2006 Sep; 12(9):870-8. PMID: 16954806
36. Goebel S, Huang M, Davis WC, Jennings M, Siahaan TJ, Alexander JS, et al. VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2006 Apr [cited 2015 Sep 25]; 290(4):G648-54. PMID: 16293653
37. Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. AGA Institute American Gastroenterological Association; 2009 Feb; 136(2):585-95.e5.
38. De Filippis D, Russo A, De Stefano D, Maiuri MC, Esposito G, Cinelli MP et al. (2007). Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappa B activation. J Mol Med 85: 635-645 PMID: 17447045
39. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005 Sep; 8(3):179-83. PMID: 16169463
40. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005 Sep; 16(8):797-803. PMID: 16096426
41. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006 May 25; 441(7092):424-30. PMID: 16724053
42. Yuan G, Nanduri J, Khan S, Semenza GL, Prabhakar NR. Induction of HIF-1alpha expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J Cell Physiol [Internet]. 2008 Dec; 217(3):674-85.
43. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001 Jun; 21(12):3995-4004. PMID: 11359907
44. Glover LE, Colgan SP. Hypoxia and metabolic factors that influence IBD pathogenesis. Gastroenterology. 2011; 140(6):1748-55. doi: 10.1053/j.gastro.2011.01.056 PMID: 21530741
45. Han S, Roman J. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics? Anticancer Drugs. 2007 Mar; 18(3):237-44. PMID: 17264754
46. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006 Sep; 55(9):1341-9. PMID: 16905700
47. Dormond-Meuwly A, Roulin D, Dufour M, Benoit M, Demartines N, Dormond O. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors. Biochem Biophys Res Commun. Elsevier Inc.; 2011 Apr 22; 407(4):714-9.
48. Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L, et al. Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide. J Cell Mol Med [Internet]. 2011 Dec; 15(12):2664-74.
49. Gee E, Milkiewicz M, Haas TL. p38 MAPK activity is stimulated by vascular endothelial growth factor receptor 2 activation and is essential for shear stress-induced angiogenesis. J Cell Physiol. 2010 Jan; 222(1):120-6. doi: 10.1002/jcp.21924 PMID: 19774558
50. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. The role of nitric oxide in cancer. Cell Res. 2002 Dec; 12(5-6):311-20. PMID: 12528889
51. Montrose DC, Nakanishi M, Murphy RC, Zarini S, McAleer JP, Vella AT, et al. The role of PGE2 in intestinal inflammation and tumorigenesis. Prostaglandins Other Lipid Mediat. 2015 Jan-Mar; 116-117:26-36 doi: 10.1016/j.prostaglandins.2014.10.002 PMID: 25460828
52. De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol. 2002 Aug; 16(4):297-302. PMID: 12570018
53. Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J. 2001 Aug 15; 358(Pt 1):249-55. PMID: 11485574
54. Tang J, Sharif O, Pai C. Mesalamine protects against colorectal cancer in inflammatory bowel disease. Digestive and Liver disease 2010; 55(6):1696
55. Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis
56. Cunliffe RN, Scott BB. Monitoring for drug side-effects in inflammatory bowel disease APT 2002 66(4):647-662
57. Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis. Pain Physician 2016; 19:11-24 PMID: 26815246
58. Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A,et al. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics. 2016 Apr; 13(2):428-38. doi: 10.1007/s13311-016-0420-z PMID: 26857391